Abstract 2124P
Background
Malnutrition affects up to 75% of cancer pts and results from a combination of anorexia and metabolic dysregulation. Metabolic and nutritional abnormalities in cancer pts can lead to cachexia, a multifactorial syndrome characterized by involuntary loss of skeletal muscle mass, systemic inflammation and increased protein catabolism. Cancer cachexia negatively affects patients’ outcomes, compliance to anticancer treatments, quality of life and survival. However, risk of malnutrition and cachexia are still under recognized in cancer pts. The Prevalence of Malnutrition in Oncology (PreMiO) study revealed that 51% of pts had nutritional impairment already at the first medical oncology visit.
Methods
The retrospective, observational NUTRIONCO study included a subpopulation (n=571 pts) of the prospective, observational PREMiO study (n=1952 pts) for whom follow-up data were collected from August 2019 to October 2021 and made available in electronic case report forms at ten medical oncology sites in Italy. The clinical outcomes that were considered for the association analysis with the baseline clinical and nutritional variables were: patient’s rehospitalization, onset of treatment-related toxicity, patient’s death and disease progression.
Results
We highlighted a statistically significant association between baseline variables and patients’ death, rehospitalization, treatment toxicity and disease progression at follow-up. We found a higher overall survival probability in well-nourished general study population vs. malnourished pts (p<0.001). Patients’ stratification revealed that malnutrition decreased the survival probability in non-metastatic pts, but not in metastatic pts (p<0.001). Multivariate analysis confirmed that baseline malnutrition (p=0.004) and VAS score for appetite loss (p=0.0104), in addition to albumin <35 g/L (p<0.0001) and neutrophil/lymphocyte ratio >3 (p=0.0007), were independently associated with death of non-metastatic pts at follow-up.
Conclusions
These findings support the importance of a proactive, early management of malnutrition and cachexia in cancer pts, and in particular in non-metastatic pts, in the perspective of a substantial improvement of their clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIOM Foundantion.
Funding
Fresenius-Kabi Italy.
Disclosure
A. Frassoldati: Financial Interests, Personal, Advisory Role: Roche, Novartis, Pfizer, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06